EdiGene, a Beijing-Cambridge, MA company that uses gene editing technology to develop novel therapeutics, completed a $10 Million Series pre-B Plus financing. The latest round was led by new investor Shenzhen Green Pine Capital Partners. Founded in 2015, EdiGene combines its CRISPR/Cas 9 gene editing technologies with high-throughput genomic screening and functional big data of underlying biology. It is developing a portfolio of candidates to treat genetic diseases and cancer. The company also offers CRO discovery services based on its CRISPR/Cas 9-based screening platforms.
Source: China Biotoday
